Although alopecia areata (AA) shows a high rate of spontaneous remission, there are many treatment options applied for rapid clinical results. Intralesional corticosteroid is first-line therapy for patients with less than 50% scalp involvement. Most s...
Although alopecia areata (AA) shows a high rate of spontaneous remission, there are many treatment options applied for rapid clinical results. Intralesional corticosteroid is first-line therapy for patients with less than 50% scalp involvement. Most studies with intralesional corticosteroid reported 60-75% of patients experienced hair regrowth within 4 months. However, if there is no regrowth after 4 months of treatment, topical corticosteroids, minoxidil and immunotherapy would be considered. Polydeoxyribonucleotide (PDRN), deoxyribonucleotide polymers ranging between 50 and 2000 base pairs, stimulates the adenosine receptor. The receptor is closely associated with the mechanism of minoxidil, used in the treatment of AA. Therefore, we presumed that PDRN would also have a clinical effect on AA, but there is limited data on the effectiveness of PDRN in AA. Herein, we report that two AA patients, recalcitrant to intralesional corticosteroid, show a significant clinical effect of hair regrowth with intralesional PDRN.